Table of Contents
1. Executive summary
2. Market Introduction
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. Research Methodology
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. Market Dynamics
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. Market Factor Analysis
5.1. Value Chain Analysis
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. GLOBAL ANTISENSE THERAPY MARKET,BY Application
6.1. Overview
6.2. Genetic Disease
6.3. Cancer
6.4. Infectious Disease
6.5. Neurodegenerative Disorders
6.6. Cardiometabolic & Renal Disorders
6.7. Ocular Disorders
6.8. Respiratory Disorders
6.9. Skin Disorders
6.10. Others
7. GLOBAL ANTISENSE THERAPY MARKET,BY Route of Administration
7.1. Overview
7.2. Intravenous Injections
7.3. Intrathecal Injections
8. GLOBAL ANTISENSE THERAPY MARKET, by Region
8.1. Overview
8.1. North America
8.1.1. US
8.1.2. Canada
8.2. Europe
8.2.1. Germany
8.2.2. France
8.2.3. UK
8.2.4. Italy
8.2.5. Spain
8.2.6. Rest of Europe
8.3. Asia-Pacific
8.3.1. China
8.3.2. India
8.3.3. Japan
8.3.4. South Korea
8.3.5. Australia
8.3.6. Rest of Asia-Pacific
8.4. Rest of the World
8.4.1. Middle East
8.4.2. Africa
8.4.3. Latin America
9. Competitive Landscape
9.1. Overview
9.2. Competitive Analysis
9.3. Market Share Analysis
9.4. Major Growth Strategy in the Global Antisense Therapy Market,
9.5. Competitive Benchmarking
9.6. Leading Players in Terms of Number of Developments in the Global Antisense Therapy Market,
9.7. Key developments and Growth Strategies
9.7.1. New ProductLaunch/Service Deployment
9.7.2. Merger &Acquisitions
9.7.3. Joint Ventures
9.8. Major Players Financial Matrix
9.8.1. Sales & Operating Income,2022
9.8.2. Major Players R&D Expenditure.2022
10. Company ProfileS
10.1. GSK plc;
10.1.1. Company Overview
10.1.2. Financial Overview
10.1.3. Products Offered
10.1.4. Key Developments
10.1.5. SWOT Analysis
10.1.6. Key Strategies
10.2. Olix Pharmaceuticals, Inc;
10.2.1. Company Overview
10.2.2. Financial Overview
10.2.3. Products Offered
10.2.4. Key Developments
10.2.5. SWOT Analysis
10.2.6. Key Strategies
10.3. Sanofi;
10.3.1. Company Overview
10.3.2. Financial Overview
10.3.3. Products Offered
10.3.4. Key Developments
10.3.5. SWOT Analysis
10.3.6. Key Strategies
10.4. Alnylam Pharmaceuticals, Inc.;
10.4.1. Company Overview
10.4.2. Financial Overview
10.4.3. Products Offered
10.4.4. Key Developments
10.4.5. SWOT Analysis
10.4.6. Key Strategies
10.5. Arbutus Biopharma;
10.5.1. Company Overview
10.5.2. Financial Overview
10.5.3. Products Offered
10.5.4. Key Developments
10.5.5. SWOT Analysis
10.5.6. Key Strategies
10.6. Benitec Biopharma Inc.;
10.6.1. Company Overview
10.6.2. Financial Overview
10.6.3. Products Offered
10.6.4. Key Developments
10.6.5. SWOT Analysis
10.6.6. Key Strategies
10.7. Silence Therapeutics;
10.7.1. Company Overview
10.7.2. Financial Overview
10.7.3. Products Offered
10.7.4. Key Developments
10.7.5. SWOT Analysis
10.7.6. Key Strategies
10.8. Ionis Pharmaceuticals, Inc;
10.8.1. Company Overview
10.8.2. Financial Overview
10.8.3. Products Offered
10.8.4. Key Developments
10.8.5. SWOT Analysis
10.8.6. Key Strategies
10.9. Bio-Path Holdings Inc..;
10.9.1. Company Overview
10.9.2. Financial Overview
10.9.3. Products Offered
10.9.4. Key Developments
10.9.5. SWOT Analysis
10.9.6. Key Strategies
10.10. Antisense Therapeutics Limited;
10.10.1. Company Overview
10.10.2. Financial Overview
10.10.3. Products Offered
10.10.4. Key Developments
10.10.5. SWOT Analysis
10.10.6. Key Strategies
11. Appendix
11.1. References
11.2. Related Reports
LIST OF TABLES
TABLE 1 Global Antisense Therapy Market, Synopsis, 2018-2032
TABLE 2 Global Antisense Therapy Market, Estimates &Forecast, 2018-2032(USD BILLION)
TABLE 3 GLOBAL ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 4 GLOBAL ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 5 North America: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 6 North America: ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 7 US: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 8 US: ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 9 Canada: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 10 Canada: ANTISENSE THERAPY MARKET,BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 1 Europe: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 2 Europe: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 3 germany: ANTISENSE THERAPY MARKET,BY Application,2018-2032 (USD BILLION)
TABLE 4 germany: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 5 FRANCE: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 6 FRANCE: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 7 italy: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 8 italy: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 9 spain: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 10 spain: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 11 UK: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 12 UK: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 13 rest of europe: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 14 rest of europe: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 15 Asia-Pacific: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 16 Asia-Pacific: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 17 japan: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 18 japan: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 19 china: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 20 china: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 21 india: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 22 india: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 23 australia: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 24 australia: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 25 south korea: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 26 south korea: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 27 rest of asia-pacific: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 28 rest of asia-pacific: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 29 rest of the world: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 30 rest of the world: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 31 Middle east: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 32 Middle east: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 33 Africa: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 34 Africa: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
TABLE 35 Latin america: ANTISENSE THERAPY MARKET,BY Application, 2018-2032 (USD BILLION)
TABLE 36 Latin america: ANTISENSE THERAPY MARKET, BY Route of Administration , 2018-2032 (USD BILLION)
LIST OF FIGURES
FIGURE 1 Research Process
FIGURE 2 Market Structure for the Global Antisense Therapy Market
FIGURE 3 Market Dynamics for the Global Antisense Therapy Market
FIGURE 4 Global Antisense Therapy Market, Share (%), BY Application, 2022
FIGURE 5 Global Antisense Therapy Market, Share (%), BY Route of Administration , 2022
FIGURE 6 Global Antisense Therapy Market, Share (%), by Region, 2022
FIGURE 7 north AMERICA: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022
FIGURE 8 Europe: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022
FIGURE 9 Asia-Pacific: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022
FIGURE 10 Rest of the world: ANTISENSE THERAPY MARKET, SHARE (%), BY REGION, 2022
FIGURE 11 Global Antisense Therapy Market: Company Share Analysis, 2022 (%)
FIGURE 12 GSK plc: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 13 GSK plc: SWOT ANALYSIS
FIGURE 14 Olix Pharmaceuticals, Inc.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 15 Olix Pharmaceuticals, Inc.:SWOT ANALYSIS
FIGURE 16 Sanofi:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 17 Sanofi:SWOT ANALYSIS
FIGURE 18 Alnylam Pharmaceuticals, Inc.: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 19 Alnylam Pharmaceuticals, Inc.:SWOT ANALYSIS
FIGURE 20 Arbutus Biopharma.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 21 Arbutus Biopharma.:SWOT ANALYSIS
FIGURE 22 Benitec Biopharma Inc:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 23 Benitec Biopharma Inc:SWOT ANALYSIS
FIGURE 24 Silence Therapeutics: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 25 Silence Therapeutics: SWOT ANALYSIS
FIGURE 26 Ionis Pharmaceuticals, Inc.:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 27 Ionis Pharmaceuticals, Inc.:SWOT ANALYSIS
FIGURE 28 Bio-Path Holdings Inc i:FINANCIAL OVERVIEW SNAPSHOT
FIGURE 29 Bio-Path Holdings Inc:SWOT ANALYSIS
FIGURE 30 Antisense Therapeutics Limited..: FINANCIAL OVERVIEW SNAPSHOT
FIGURE 31 Antisense Therapeutics Limited.:SWOT ANALYSIS
